News Archive

13 Jun. 2008

GMP Certificate Granted to Biomay

As of July 2008, the Austrian Agency for Health and Food Safety (AGES) grants to Biomay the certificate of GMP compliance.[more]

2 Jun. 2008

Hans Huber new Head of Production at Biomay

Biomay announces that Dr. Hans Huber joins the Management Team as Head of GMP Production. He will be responsible for GMP manufacture, production development and process science.[more]

26 Nov. 2007

New CD Laboratory for Immunmodulation Supported by Biomay

A new Christian Doppler Laboratory for Immunmodulation was inaugurated by Johannes Hahn, Federal Minister for Science and Research.[more]

2 Oct. 2007

"science2business-award" for Cooperation of University Salzburg and Biomay

The „science2business award” for the best cooperation between industry and science was granted to the University of Salzburg and Biomay with their Christian Doppler Laboratory “Allergy Diagnosis and Therapy”.[more]

8 Jan. 2007

Biomay Recruits Ursula Baumgartner as Quality Manager

Biomay recruits Dr. Ursula Baumgartner as Quality Manager, who will be responsible for the establishment of a GMP-compliant quality system.[more]

31 Jul. 2006

CD Lab for Allergy Diagnosis and Therapy in Salzburg

At the University of Salzburg, the Christian Doppler Laboratory of Allergy Diagnosis and Therapy was opened by Governor Gabriele Burgstaller.[more]

9 Mar. 2006

Stallergenes Reports Positive Study Results with Biomay´s Bet v 1

Stallergenes (Antony Cedex, France) reported successful results of a proof of concept study with recombinant Bet v 1 produced under a license agreement with Biomay.[more]

23 Feb. 2006

Biomay Supports New Cristian Doppler Lab for Allergy Research

The Christian Doppler Research Association (CDG) opened a new laboratory for Allergy Research at the Department of Pathophysiology, Medical University of Vienna (MUV).[more]

Displaying 31 to 38 of 38
<< First < Previous 1-10 11-20 21-30 31-38 Next > Last >>

Biomay AG completes capital increase in the amount of €2.8 million from existing investors

Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com